Company

MyoGene Bio

Rocket Ship Rating

Rocket Ship Rating: 85 out of 100

To Develop Cutting Edge Genetic Therapies for Muscle Diseases

Also known as Myogenebio

Biotech & therapeutics
Deeptech

Status: Operatingas of 2026-09-18
Business model: B2B

Open relationship map

Claim, correct or request removal

Record updated 28 September 2026

About

Our lead program is a gene editing therapy, MyoDys 45-55 , for Duchenne muscular dystrophy (DMD), a devastating, fatal muscle wasting disease.

Funding snapshot

Total raised: $4.8MSum of rounds, as of 2026-09-18Source (opens in a new tab)
Latest round: Grant, $1.4M2025-11-04

Funding rounds

Grant: $1.4M2025-11-04, Company stated
Grant: 2025-05-15
Grant: 2024-09-01
Round, 2023: 2023-05-11
Grant: $3.4M2021-12-15, Company stated
Grant: 2020-09-05
Grant: 2019-09-05

Products

Other: MyoDys 45-55